Danish Appeals Permission Board grants leave of appeal
Announcement
16 March 2016
The Danish Appeals Permission Board today granted NeuroSearch leave of appeal to the Supreme Court of the judgment delivered by the Eastern Division of the Danish High Court on 14 October 2015. The High Court fined NeuroSearch DKK 5 million for violation of the prohibition against price manipulation of section 39(1), cf. section 38(1), of the Danish Securities Trading Act.
Pending the Supreme Court’s judgment, NeuroSearch will as soon as possible and with due consideration of the interests of its shareholders seek to continue the disposal of the company’s assets.
Outlook for 2016
In 2016, NeuroSearch expects an operating loss in the range of DKK 4-6 million including income from Saniona. The outlook does not include any income from the possible sale of Company assets, other potential income from the Company's agreements with Teva or others, and neither does the outlook take into account a potential reversal of the provision of DKK 5 million made to cover the fine the Company has been ordered to pay.
Contact
Allan Andersen
CEO, mobile +45 4016 3864
About NeuroSearch
NeuroSearch A/S (NEUR) is listed on NASDAQ Copenhagen A/S.
Vedhæftede filer:
Procesbevillingsnævnet til Højeste ret UK.pdf